Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh

This study has been completed.
Sponsor:
Information provided by:
University of Cambridge
ClinicalTrials.gov Identifier:
NCT00607074
First received: January 22, 2008
Last updated: February 4, 2008
Last verified: January 2008
  Purpose

This longitudinal study aimed to assess whether regular anti-Giardia and antihelmintic treatment improved growth and small intestinal mucosal function of rural Bangladeshi infants.


Condition Intervention
Giardiasis
Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
Drug: Anti-Giardia treatment only (secnidazole or albendazole)
Drug: Control group (placebo)

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: Effects of Anti-Giardia and Antihelmintic Treatment on Infant Nutritional and Biochemical Status and Intestinal Permeability in Rural Bangladesh

Resource links provided by NLM:


Further study details as provided by University of Cambridge:

Primary Outcome Measures:
  • nutritional status [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • intestinal permeability [ Time Frame: 9 months ] [ Designated as safety issue: No ]

Enrollment: 410
Study Start Date: June 2003
Study Completion Date: December 2006
Primary Completion Date: April 2004 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
Drug: Anti-Giardia treatment only (secnidazole or albendazole)
Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
Drug: Control group (placebo)
Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo

Detailed Description:

A randomised double-blind controlled intervention of 36 weeks duration was conducted in a rural community located 40kms north-west of Dhaka, the capital of Bangladesh. Infants aged between 3 and 11 months were randomly assigned to either receiving anti-Giardia and antihelmintic treatment, or anti-Giardia treatment only, or a control group receiving placebos. Weight and supine length were recorded every 4 weeks. Every 12 weeks intestinal permeability (L/M ratio), haemoglobin, plasma albumin, alpha-1-acid glycoprotein, immunoglobulin G and Giardia intestinalis specific IgM titre (GSIgM) and eggs of the three common geohelminths and Giardia intestinalis cysts were determined.

  Eligibility

Ages Eligible for Study:   3 Months to 15 Months
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • infants living in the study area
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00607074

Locations
Bangladesh
National Institute of Preventive and Social Medicine
Mohakhali, Dhaka, Bangladesh, 1212
Sponsors and Collaborators
University of Cambridge
Investigators
Study Chair: Nicholas C Mascie-Taylor, ScD Department of Biological Anthropology, University of Cambridge
  More Information

No publications provided by University of Cambridge

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Dr Rie Goto, Department of Biological Anthropology, University of Cambridge
ClinicalTrials.gov Identifier: NCT00607074     History of Changes
Other Study ID Numbers: BMRC/ERC/2001-2004/2281, BMRC/ERC/2001-2004/2281
Study First Received: January 22, 2008
Last Updated: February 4, 2008
Health Authority: Bangladesh: Ethical Review Committee

Additional relevant MeSH terms:
Giardiasis
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Intestinal Diseases, Parasitic
Parasitic Diseases
Protozoan Infections
Albendazole
Anthelmintics
Metronidazole
Secnidazole
Anti-Infective Agents
Anticestodal Agents
Antimitotic Agents
Antineoplastic Agents
Antiparasitic Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Radiation-Sensitizing Agents
Therapeutic Uses
Tubulin Modulators

ClinicalTrials.gov processed this record on October 23, 2014